Genistin modulates high-mobility group box protein 1 (HMGB1) and nuclear factor kappa-B (NF-κB) in...

Area of Science:

• Oncology
• Natural Product Chemistry
• Molecular Biology

Background:

• Cancer is a leading cause of death globally, with existing treatments facing challenges like side effects and drug resistance.
• Targeting inflammation and apoptosis are critical research areas for novel cancer therapies.
• Natural compounds, particularly flavonoids, offer potential as safe, cost-effective anti-cancer agents with high bioavailability.

Purpose of the Study:

• To evaluate the in vitro and in vivo anti-cancer properties of the isolated flavonoid, genistin.
• To investigate genistin's effects on breast cancer cell lines and tumor growth in vivo.
• To elucidate the molecular mechanisms underlying genistin's anti-cancer activity, focusing on inflammation and apoptosis pathways.

Main Methods:

• In vitro antiproliferative assays using human breast cancer cell lines (MCF-7 and MDA-MB-231).
• In vivo studies using Ehrlich's ascites carcinoma (EAC) model to assess tumor growth inhibition.
• Measurement of key molecular markers including high-mobility group box1 (HMGB1), nuclear factor-kappa B (NF-κB), and B-cell lymphoma 2 (Bcl-2).

Main Results:

• Genistin demonstrated significant cytotoxic activity against both MCF-7 and MDA-MB-231 breast cancer cell lines in vitro.
• In vivo, genistin treatment led to a significant reduction in tumor weight and volume in the EAC model.
• Genistin decreased HMGB1 and NF-κB levels while increasing Bcl-2 expression, indicating anti-inflammatory and anti-apoptotic effects.

Conclusions:

• Genistin exhibits potent cytotoxic and antiproliferative effects against breast cancer cells.
• The anti-cancer activity of genistin is mediated through the inhibition of HMGB1 signaling and activation of the Bcl-2 pathway, suggesting anti-inflammatory and anti-apoptotic properties.
• Genistin represents a promising natural compound for developing novel, cost-effective cancer therapies.